Canaccord lowered the firm’s price target on Mind Medicine to $14 from $16 and keeps a Buy rating on the shares. The firm views the stock as signifcantly undervalued following its Q2 results and recent capital raise while noting catalysts are some time away.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNMD: